660 related articles for article (PubMed ID: 16603719)
1. Cyclin-dependent kinase pathways as targets for cancer treatment.
Shapiro GI
J Clin Oncol; 2006 Apr; 24(11):1770-83. PubMed ID: 16603719
[TBL] [Abstract][Full Text] [Related]
2. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Cai D; Byth KF; Shapiro GI
Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
[TBL] [Abstract][Full Text] [Related]
3. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
6. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
8. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
[TBL] [Abstract][Full Text] [Related]
9. CDK regulators-Cell cycle progression or apoptosis-Scenarios in normal cells and cancerous cells.
Nilmani ; D'costa M; Bothe A; Das S; Udhaya Kumar S; Gnanasambandan R; George Priya Doss C
Adv Protein Chem Struct Biol; 2023; 135():125-177. PubMed ID: 37061330
[TBL] [Abstract][Full Text] [Related]
10. Histone acetylation and the cell-cycle in cancer.
Wang C; Fu M; Mani S; Wadler S; Senderowicz AM; Pestell RG
Front Biosci; 2001 Apr; 6():D610-29. PubMed ID: 11282573
[TBL] [Abstract][Full Text] [Related]
11. Early development of cyclin dependent kinase modulators.
Roy KK; Sausville EA
Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
[TBL] [Abstract][Full Text] [Related]
12. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Bose P; Simmons GL; Grant S
Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
15. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Senderowicz AM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
[TBL] [Abstract][Full Text] [Related]
16. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
18. [Cell cycle regulation after exposure to ionizing radiation].
Teyssier F; Bay JO; Dionet C; Verrelle P
Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340
[TBL] [Abstract][Full Text] [Related]
19. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
20. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Węsierska-Gądek J; Kramer MP
Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
